Silo Pharma, INC 10-Q quarterly reports

Silo Pharma, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing research and development efforts in biopharmaceuticals and a cryptocurrency treasury strategy, alongside financial results showing continued net losses.

Silo Pharma reported an increased net loss in Q3 2025, driven by higher R&D expenses and accelerated license amortization, while launching a new cryptocurrency treasury strategy.

Silo Pharma, a biopharmaceutical company, reported a significantly wider net loss for the first half of 2025 while announcing a new cryptocurrency treasury strategy and facing a Nasdaq minimum bid price deficiency.

Silo Pharma reports a net loss for Q1 2025 while advancing its pipeline of novel therapeutics targeting PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis.

Silo Pharma's Q3 2024 report reveals increased research and development expenses and recent capital raises, alongside a net loss of $2.66 million for the nine-month period.

Silo Pharma's second quarter 2024 results show a net loss, but the company is progressing with its drug development programs and has secured additional funding.

Silo Pharma reported a net loss of $801,667 for the first quarter of 2024, while advancing its pipeline of novel therapeutics.